The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Li, Yuan ^a   Yi, Haiying ^b   Yao, Yixin ^a   Liao, Xiaodong ^a   Xie, Yiqun ^b   Yang, Jie ^a   Yan, Zheng ^a   Wang, Long ^c   Lu, Shunyuan ^c   Kuang, Ying ^c   Gu, Mingmin ^a   Fei, Jian ^c   Wang, Zhugang ^a,c   Huang, Lei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Huangpu Dist Ctrl Hosp   (China)

^c Shanghai Research Center for Model Organisms   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; MUCIN 1; MYC PROTEIN;

ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST DEVELOPMENT; BREAST HYPERPLASIA; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE OVEREXPRESSION; GENOTYPE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION; SPECIES DIFFERENCE; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE; ANIMAL; BREAST TUMOR; C57BL MOUSE; CHEMISTRY; HYPERPLASIA; METABOLISM; PATHOLOGY; PHYSIOLOGY; UDDER;

MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

ANIMALS; BREAST NEOPLASMS; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; FEMALE; HYPERPLASIA; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCIN-1;

EID: 79955393508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019102     Document Type: Article

References (58)

1. Hennighausen L, Robinson GW, (2001) Signaling pathways in mammary gland development. Dev Cell 1: 467-475.
2. Moraes RC, Zhang X, Harrington N, Fung JY, Wu MF, et al. (2007) Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development 134: 1231-1242.
3. Boras-Granic K, Wysolmerski JJ, (2008) Wnt signaling in breast organogenesis. Organogenesis 4: 116-122.
4. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, et al. (2009) MMTV-Wnt1 and-DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS One 4: e4537.
5. Zhang J, Li Y, Liu Q, Lu W, Bu G, (2010) Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis. Oncogene 29: 539-549.
6. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, et al. (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382: 638-642.
7. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, et al. (2000) Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 14: 650-654.
8. Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P, (2001) Delta N89 beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol 153: 555-568.
9. Teuliere J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, et al. (2005) Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development 132: 267-277.
10. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, et al. (1984) Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3: 223-232.
11. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J, (1988) Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11-12: 55-101.
12. Huang L, Chen D, Liu D, Yin L, Kharbanda S, et al. (2005) MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 65: 10413-10422.
13. Li Y, Liu D, Chen D, Kharbanda S, Kufe D, (2003) Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 22: 6107-6110.
14. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ, (2003) MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22: 1324-1332.
15. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ, (2001) Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 276: 13057-13064.
16. Poh TW, Bradley JM, Mukherjee P, Gendler SJ, (2009) Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow. Cancer Res 69: 3554-3562.
17. Spicer AP, Duhig T, Chilton BS, Gendler SJ, (1995) Analysis of mammalian MUC1 genes reveals potential functionally important domains. Mamm Genome 6: 885-888.
18. Brayman M, Thathiah A, Carson DD, (2004) MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2: 4.
19. Kufe DW, (2008) Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol Ther 7: 81-84.
20. Li Y, Ren J, Yu W, Li Q, Kuwahara H, et al. (2001) The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem 276: 35239-35242.
21. Yamamoto M, Bharti A, Li Y, Kufe D, (1997) Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 272: 12492-12494.
22. Li Y, Bharti A, Chen D, Gong J, Kufe D, (1998) Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 18: 7216-7224.
23. Li Y, Kuwahara H, Ren J, Wen G, Kufe D, (2001) The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 276: 6061-6064.
24. Ren J, Li Y, Kufe D, (2002) Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 277: 17616-17622.
25. Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, et al. (2004) MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 23: 5739-5747.
26. Wen Y, Caffrey TC, Wheelock MJ, Johnson KR, Hollingsworth MA, (2003) Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 278: 38029-38039.
27. Huang L, Ren J, Chen D, Li Y, Kharbanda S, et al. (2003) MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther 2: 702-706.
28. Pierce DF Jr, Johnson MD, Matsui Y, Robinson SD, Gold LI, et al. (1993) Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev 7: 2308-2317.
29. Zhao X, Ren W, Yang W, Wang Y, Kong H, et al. (2006) Wnt pathway is involved in pleomorphic adenomas induced by overexpression of PLAG1 in transgenic mice. Int J Cancer 118: 643-648.
30. Guy CT, Cardiff RD, Muller WJ, (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961.
31. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
32. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, et al. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 96: 5522-5527.
33. Tetsu O, McCormick F, (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
34. Moser AR, Hegge LF, Cardiff RD, (2001) Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc(min)/+ mice. Cancer Res 61: 3480-3485.
35. Blake JA, Richardson JE, Davisson MT, Eppig JT, (1999) The Mouse Genome Database (MGD): genetic and genomic information about the laboratory mouse. The Mouse Genome Database Group. Nucleic Acids Res 27: 95-98.
36. Kumar R, Vadlamudi RK, Adam L, (2000) Apoptosis in mammary gland and cancer. Endocr Relat Cancer 7: 257-269.
37. Medina D, (1996) The mammary gland: a unique organ for the study of development and tumorigenesis. J Mammary Gland Biol Neoplasia 1: 5-19.
38. Huang L, Liao X, Beckett M, Li Y, Khanna KK, et al. (2010) MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation. Genes Cancer 1: 239-250.
39. Raina D, Kharbanda S, Kufe D, (2004) The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 279: 20607-20612.
40. Ren J, Agata N, Chen D, Li Y, Yu WH, et al. (2004) Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5: 163-175.
41. Yin L, Huang L, Kufe D, (2004) MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem 279: 45721-45727.
42. Yin L, Li Y, Ren J, Kuwahara H, Kufe D, (2003) Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 278: 35458-35464.
43. Wei X, Xu H, Kufe D, (2006) MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 21: 295-305.
44. Hens JR, Wysolmerski JJ, (2005) Key stages of mammary gland development: molecular mechanisms involved in the formation of the embryonic mammary gland. Breast Cancer Res 7: 220-224.
45. Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, et al. (2004) Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development 131: 4819-4829.
46. Boras-Granic K, Chang H, Grosschedl R, Hamel PA, (2006) Lef1 is required for the transition of Wnt signaling from mesenchymal to epithelial cells in the mouse embryonic mammary gland. Dev Biol 295: 219-231.
47. Van Genderen C, Okamura RM, Farinas I, Quo RG, Parslow TG, et al. (1994) Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev 8: 2691-2703.
48. Tepera SB, McCrea PD, Rosen JM, (2003) A beta-catenin survival signal is required for normal lobular development in the mammary gland. J Cell Sci 116: 1137-1149.
49. Sutherland RL, Musgrove EA, (2002) Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 4: 14-17.
50. Yu Q, Geng Y, Sicinski P, (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021.
51. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, et al. (1994) Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57: 353-361.
52. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, et al. (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54: 1812-1817.
53. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, et al. (1995) Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11: 885-891.
54. Deming SL, Nass SJ, Dickson RB, Trock BJ, (2000) C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83: 1688-1695.
55. Amundadottir LT, Merlino G, Dickson RB, (1996) Transgenic mouse models of breast cancer. Breast Cancer Res Treat 39: 119-135.
56. Nass SJ, Dickson RB, (1997) Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44: 1-22.
57. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, et al. (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669-671.
58. Djonov V, Andres AC, Ziemiecki A, (2001) Vascular remodelling during the normal and malignant life cycle of the mammary gland. Microsc Res Tech 52: 182-189.